Answers are grounded in this paper and cite their sources.
Background: Since December 2019, the COVID-19 pandemic has caused the dead of 1 million people, from these critically ill patients have an increased risk of bacteremia. Material and Methods: This observational, retrospective, single-center study included 129 critically ill COVID-19 patients with a bacteremia. We studied the clinical characteristics, comorbidities, hospital and intensive care unit length of stay, days on invasive mechanical ventilation, maximum dose of norepinephrine and mortality. Results: From 129 patients were reported 17 patients (13.2%) with bacteremia. 35.3% were cataloged as a primary bacteremia. The source of secondary bacteremia was a ventilator associated pneumonia in 81.8%, central line-associated blood stream infection in 18.1% and urinary catheter infection in 9%. The patients with bacteremia, had a hospitalization stay of 23 days Vs. 20.5 days in the patients without bacteremia (p=0.19); 18 Vs. 13.5 days in the ICU (p=0.061); 15 Vs 11 days on IMV (p=0.053) and a maximum dose of norepinephrine of 0.28 Vs. 0.11 mcg/kg/min (p=0.02). We reported a 14.8% of mortality in patients with bacteremia vs. 12.7% in patients without bacteremia, odds ratio of 0.87 (p=0.75). Conclusion: Critically ill COVID-19 patients and bacteremia tend to increase the length of stay in the ICU and days on IMV with no change in mortality.
No takes yet. Share an insight, caveat, or question.
Daniel et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: